65,437 trials
Hepatitis C
Primary: Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 (SVR12) — 87.5; 92.3 percentage of participants
Hypertension
Primary: Change in Trough Sitting Diastolic Blood Pressure (SiDBP)-Double-Blind Treatment Period — -12.1; -6.2 mmHg — p=<0.001
Sepsis · Severe Sepsis · Septic Shock
Primary: Hospital Mortality — 92; 81; 86 Participants
Sexual Dysfunction · Breast Cancer Survivors
Primary: Change of Pain Score of Female Sexual Function Index — 1.15; 1.05 units on a scale
Multiple Sclerosis
Primary: Lipoic Acid Levels — 1376.14; 1609.07; 1428.05 ng/mL
Blood Cancer · Leukemia · Graft Versus Host Disease
Primary: Engraftment of Haploidentical CD34+ Selected Blood Stem Cells in Older Patients or Those With Medical Co-morbidities Following Total Lymphoid Irradiation and…
Influenza
Primary: Number of Subjects Seroconverted for HI Antibodies Against Flu A/CAL/7/09 H1N1 Strain — 63; 58; 61; 96 Subjects
Relapsing Multiple Sclerosis
Primary: Percentage of Participants Experiencing New or Increased FLS During the First 8 Weeks: Overall Population — 10.3 percentage of participants — p=<0.0001
Jaw, Edentulous, Partially
Primary: Number od Participants With Consistent Connective Tissue Integration at a Histologic Level — 10; 10 participants
Gastrointestinal Bleeding
Primary: Rebleeding Rate — 97 participants
Asthma
Primary: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL — 0.6; 0.66; 0.93 Events/year…
COPD · COPD Exacerbation · Lung Diseases
Primary: Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year. — 1.27; 1.17 COPD exacerbations per patient per year — p=0.1634
Lung Cancer
Primary: Progression-free Survival at 6 Months — 60 percentage of participants
Lung Cancer
Primary: Overall Survival at 2 Years — 69.8 percentage of participants
Opiate Dependence
Primary: Illicit Opioid Use — 35.2; 53.2 percent of opioid negative urine samples